Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 12/20 | 0.88 |
| ▸ | MET | P08581 | 12/20 | 0.88 |
| ▸ | KDR | P35968 | 6/20 | 0.88 |
| ▸ | MERTK | Q12866 | 6/20 | 0.80 |
| ▸ | RET | P07949 | 3/20 | 0.72 |
| ▸ | KIT | P10721 | 3/20 | 0.72 |
| ▸ | FLT3 | P36888 | 3/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.72 |
| ▸ | FLT1 | P17948 | 4/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.71 |
| ▸ | AURKA | O14965 | 2/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.71 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.71 |
| ▸ | LCK | P06239 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693516 | 1.00 | AXL (0.88) | AXLMETKDRMERTKRET | |
| SCHEMBL21260785 | 0.97 | MET (0.82) | AXLMETKDRMERTKRET | |
| SCHEMBL29693534 | 0.96 | AXL (0.88) | AXLMETKDRMERTKRET | |
| SCHEMBL372296 | 0.96 | AXL (0.88) | AXLMETKDRMERTKRET | |
| SCHEMBL29693431 | 0.96 | AXL (0.88) | AXLMETKDRMERTKRET | |
| Exelixis SCHEMBL371899 | 0.94 | MET (1.00) | AXLMETKDRMERTKRET | |
| Exelixis SCHEMBL29693473 | 0.94 | MET (1.00) | AXLMETKDRMERTKRET | |
| SCHEMBL13211063 | 0.91 | MET (0.73) | AXLMETKDRMERTKRET | |
| SCHEMBL16083186 | 0.90 | MET (0.93) | AXLMETKDRMERTKRET | |
| SCHEMBL22521242 | 0.90 | MET (0.72) | AXLMETKDRMERTKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3950677-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | AXL 109/4885MET 3/4885KDR 4/4885 |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | HDAC11, HDAC1, HDAC6 | AXL 1078/4885MET 579/4885KDR 1621/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | AXL 3814/4885MET 1701/4885KDR 3355/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | AXL 147/4885MET 8/4885KDR 60/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | AXL 109/4885MET 3/4885KDR 4/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | AXL 507/4885MET 28/4885KDR 241/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | AXL 239/4885MET 2/4885KDR 5/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | AXL 241/4885MET 2/4885KDR 5/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | AXL 241/4885MET 2/4885KDR 5/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | AXL 109/4885MET 3/4885KDR 4/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | AXL 437/4885MET 1893/4885KDR 3201/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | AXL 239/4885MET 2/4885KDR 5/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | AXL 437/4885MET 1893/4885KDR 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.